Trial Profile
Safety, tolerability and pharmacokinetic of pegvisomant subcutaneous injection in healthy Asian subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Oct 2015
Price :
$35
*
At a glance
- Drugs Pegvisomant (Primary)
- Indications Acromegaly
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 13 Oct 2015 New trial record